Trial Profile
De novo and Acquired Resistance Mutations in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) undergoing Treatment with Abiraterone Acetate or Enzalutamide in Routine Clinical Care
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 14 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress